Extended blood stage sensitivity profiles of <i>Plasmodium cynomolgi</i> to doxycycline and tafenoquine, as a model for <i>Plasmodium vivax</i>-Reference-Cited by-同舟云学术

Extended blood stage sensitivity profiles of Plasmodium cynomolgi to doxycycline and tafenoquine, as a model for Plasmodium vivax

Published:2024-05-02 Issue:5 Volume:68 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Christensen Peter¹²,Cinzah Rosy¹,Suwanarusk Rossarin¹,Chua Adeline Chiew Yen³,Kaneko Osamu⁴,Kyle Dennis E.⁵^ORCID,Aung Htin Lin¹²^ORCID,Matheson Jessica¹,Bifani Pablo⁶,Rénia Laurent³⁶,Cook Gregory M.¹²^ORCID,Snounou Georges⁷,Russell Bruce¹⁴^ORCID

Affiliation:

1. Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand

2. Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand

3. A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), , Singapore

4. Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Sakamoto, Nagasaki, Japan

5. Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA

6. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

7. 11-Université Paris-Saclay, Inserm, CEA, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB/IDMIT/UMR1184), Fontenay-aux-Roses & Kremlin- Bicêtre, Le Kremlin-Bicêtre, France

Abstract

ABSTRACT Testing Plasmodium vivax antimicrobial sensitivity is limited to ex vivo schizont maturation assays, which preclude determining the IC50s of delayed action antimalarials such as doxycycline. Using Plasmodium cynomolgi as a model for P. vivax , we determined the physiologically significant delayed death effect induced by doxycycline [IC 50(96 h) , 1,401 ± 607 nM]. As expected, IC 50(96 h) to chloroquine (20.4 nM), piperaquine (12.6 µM), and tafenoquine (1,424 nM) were not affected by extended exposure.

Funder

Manatu Hauora | Health Research Council of New Zealand

Agence Nationale de la Recherche

Agency for Science, Technology and Research

Publisher

American Society for Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00280-24

Reference22 articles.

1. Plasmodium vivax in vitro continuous culture: the spoke in the wheel

2. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and temporal modelling study

3. Resistance to Therapies for Infection by Plasmodium vivax

4. Human ex vivo studies on asexual Plasmodium vivax: The best way forward

5. Multiple Antibiotics Exert Delayed Effects against the Plasmodium falciparum Apicoplast